Faculty

Dr. Crawford is chief of medical oncology at Duke University Medical Center and associate director of clinical research at the Duke Comprehensive Cancer Center. Dr. Crawford has led many investigations of U.S. trials of cancer drugs, several of which led to FDA approval, with a focus on new agents in lung cancer and hematopoietic growth factors. He is editor-in-chief of Cancer Supportive Therapy and serves on several editorial boards of other cancer journals. Dr. Crawford earned his bachelor’s degree at Ohio Wesleyan University and his medical degree at Ohio State University. He was an intern, junior assistant resident and senior assistant resident at Duke from 1974-77, and hematology/oncology fellow at Duke from 1977-81. In 1978-79, Dr. Crawford was chief resident in medicine at Duke University/Veteran’s Administration Medical Center, and later a geriatric fellow from 1979-82. In 2003, Duke honored Dr. Crawford with the Joseph Greenfield Research Faculty Award. This was on the heels of the Wayne Rundles Award for Excellence in Clinical Research that Duke bestowed upon him in 2002 and the Wendell Rosse Teaching Award in 2000. In 2003, he earned membership in Alpha Omega Alpha. He currently holds several position s with the National Comprehensive Cancer Network, including chair of the Myeloid Growth Factor Committee and member of both the Clinical Trials Network Investigator Steering Committee and the Small Cell Lung Cancer Guidelines Committee. He also chairs committees for the American Society of Clinical Oncology and the Multinational Association of Supportive Care. Dr. Crawford has served as principal investigator for Cancer and Leukemia Group B clinical trials at Duke for more than a decade and is vice chair of the CALGB respiratory committee. In 2005, he was awarded the George Barth Geller, MD Professor for Research in Cancer.

has been Professor of Medicine in the Department of Medicine at the University of Washington in Seattle for more than 25 years. He received a medical degree from Harvard University, residency training at the Massachusetts General Hospital and the University of Washington and served as a senior investigator with the National Institute of Allergy and Infectious Diseases’ Laboratory of Clinical Investigation at the National Institutes of Health in Bethesda, Maryland. Other past positions include serving as dean of the School of Medicine at the University of Washington.

Dr. Dale is president-elect of the American College of Physicians (ACP) for 2006-2007, editor-in-chief of ACP Medicine, and an editorial board member of Clinical Advances in Hematology and Oncology and Journal of Experimental Hematology. His research interests center on neutrophil physiology, neutropenia, and hematopoietic growth factors, and he has published widely on these subjects in journals such as Supportive Cancer Therapy, Journal of Supportive Oncology, Drugs, Seminars in Oncology, Journal of Clinical Oncology, Blood and American Journal of Hematology. He has also written chapters and sections for the Merck Manual, Williams Hematology, Blood: Principles and Practice of Hematology, Clinical Hematology and ACP Medicine 2006.

Dr. Dale currently serves on the National Board of Sponsors for Physicians for Social Responsibility and is co-director of the Severe Chronic Neutropenia International Registry.

Dr. Lyman is currently Professor of Medicine and Oncology at the University of Rochester School of Medicine and Dentistry and Director of Health Services and Outcomes Research at the James P Wilmot Cancer Center at the University of Rochester Medical Center in Rochester, New York. Dr Lyman received his undergraduate and medical degree from the State University of New York at Buffalo. He then pursued a residency in medicine at the University of North Carolina in Chapel Hill and a fellowship in Medical Oncology and Hematology at the Roswell Park Memorial Institute. Dr Lyman did additional postdoctoral training in biostatistics at the Harvard School of Public Health and the Dana Farber Cancer Institute in Boston. He was previously on the faculty of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida where he was Professor of Medicine and Chief of the Medical Service as well as Professor of Epidemiology and Biostatistics at the School of Public Health.

From 1997-1998 he was Visiting Professor in the Biostatistics Unit of the London School of Hygiene and Tropical Medicine. From 2000-2002 he was the Thomas Ordway Professor of Medicine and Director of the Division of Hematology/ Oncology in the Department of Medicine at the Albany Medical College and Director of the Cancer Center at the Albany Medical Center. He also served as Professor of Biometry and Statistics at SUNY-Albany School of Public Health.

Professor Lyman is board certified in internal medicine, medical oncology and hematology. He is a fellow of the Royal College of Physicians (Edin), the American College of Physicians, the American College of Clinical Pharmacology and the American College of Preventive Medicine. Dr Lyman’s research interests include the design and analysis of clinical trials, evidence based medicine and clinical reasoning, health technology assessment and pharmacoeconomic analysis. He is also involved in the development of mathematical and statistical prognostic and predictive models to enhance the targeted and cost-effective application of new molecular diagnostic and therapeutic modalities.

Christopher R. Friese, RN, PhD, AOCN^®
Research Fellow
Center for Outcomes & Policy Research
Dana-Farber Cancer Institute/Harvard School of Public Health
Boston, MA

Christopher R. Friese, RN, PhD, AOCN^® is currently research fellow at the Center for Outcomes and Policy Research and Associate Clinical Scientist at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is also a fellow in Cancer Prevention and Control at the Harvard School of Public Health. Dr. Friese conducts research on outcomes of care for patients with cancer, and organizational factors associated with quality of care. He is principal investigator of the Oncology Nursing Society Foundation–funded study Neutropenia Outcomes: Nurse Staffing and Practice Environment Effects. He has received research funding from the National Institute of Nursing Research, the American Cancer Society, and the Oncology Nursing Society. He completed his bachelor, masters, and doctoral degrees at the University of Pennsylvania. He serves on the advisory board of the doctoral program in nursing, cancer, and health disparities at the University of Massachusetts-Boston.

Dr. Friese received a Young Investigator award from the Multinational Association of Supportive Care in Cancer in 2005 and a Merit Award from the American Society of Clinical Oncology in 2006. He lectures nationally and internationally on the topic of supportive care in cancer. His research findings have been published in Nursing Research, Oncology Nursing Forum, and the Clinical Journal of Oncology Nursing. He is research consultant and co-author of the Oncology Nursing Society’s Putting Evidence Into Practice: Evidence Based Summary for the Prevention of Infection. He has practiced in some of the nation’s leading cancer centers, including the Kimmel Cancer Center at Johns Hopkins, the Abramson Cancer Center at the University of Pennsylvania, and the Fox Chase Cancer Center. Dr. Friese remains an active nurse clinician in the hematologic malignancies/bone marrow transplant setting.

Medical Writer

Disclosure Policy

It is the policy of ArcMesa Educators to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors are expected to disclose any relevant financial relationships they may have with commercial interests in relation to this activity. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of ArcMesa Educators.

Faculty Disclosure Declarations

Jeffrey C. Crawford, MD – Grants/Research Support recipient, Advisory Board, Honorarium recipient – Amgen

David C. Dale, MD – Consultant, Speakers’ Bureau, Grants/Research Support recipient - Amgen

Gary H. Lyman, MD, MPH, FRCP (Edin) – Speakers’ Bureau, Grants/Research Support recipient – Amgen; Speaker’s Bureau – Ortho Biotech

Christopher R. Friese, RN, PhD, AOCN^® – Consultant, Speakers’ Bureau/Honorarium recipient, Stock Shareholder – Amgen; Stock Shareholder – Novartis

Shanna J. McClennen, PhD (Medical Writer) – Nothing to disclose

Printer settings may vary. Please use landscape layout option.

Copyright © 2006 ArcMesa Educators / CMEdiscovery.com. All rights reserved.